Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

You can unsubscribe at any time and we'll never share your details to third parties. More information Privacy policy. We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.

share this! Home Diabetes Home Biomedical technology. Editors' notes. Editors have highlighted the following attributes while ensuring the content's credibility: fact-checked peer-reviewed publication trusted source proofread.

Dually glucose-responsive complex for insulin delivery. Schematic of complex formation and insulin release with dual glucose-responsive mechanisms. The negatively charged diol moiety-containing Glu-insulin and the positively charged PBA moiety-containing PLL-FPBA can form a complex through electrostatic attraction and PBA—diol binding.

Upon exposure of the complex to a solution with a high level of glucose, binding of glucose to the FPBA moiety instantly reduces the positive charge density on PLL-FPBA and disrupts the PBA—diol bonds, resulting in immediate insulin release. Credit: Nature Biomedical Engineering This document is subject to copyright.

Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only. Explore further. Companies are adopting feminist narratives to influence women's health, researchers argue 4 hours ago.

Related Stories. Weekly insulin injections could be as effective in diabetes management as daily injection regimes Oct 30, Apr 14, Jan 18, Once-weekly insulin icodec with dosing guide app shows superior HbA1c reduction vs. once-daily insulin in Phase 3a trial Sep 25, Jun 17, May 31, Recommended for you.

Research team creates novel rabies viral vectors for neural circuit mapping 8 hours ago. Wound-homing molecule found to accelerate tissue repair 11 hours ago.

Load comments 0. Let us know if there is a problem with our content. Your message to the editors. Your email only if you want to be contacted back. Send Feedback. Thank you for taking time to provide your feedback to the editors. E-mail the story Single 'smart' insulin injection regulates glucose levels in mice and minipigs up to one week.

Your friend's email. Your email. Terms and conditions apply. Your healthcare team can help you figure out what therapy will work best for you. If you would like tips for discussing smart insulin pen at your next appointment, check out our discussion guide.

The InPen is the only FDA-cleared smart 3 insulin pen that combines the freedom of Bluetooth ® technology and intelligence through an easy to use smartphone app, helping people administer correction and mealtime insulin doses.

InPen is a prescription-only device. Each InPen is reusable for one year. Yes, you can pair as many InPens as you need to the app. This enables the flexibility for you to have one InPen at home and another at work or school.

Note: Make sure your paired device is within range of your InPen when you dose. Your InPen app will automatically sync doses from all paired InPen s when within range. References Φ Compensated for time. Thoughts and opinions are individual's own. Offer available to eligible patients with commercial insurance.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license. A healthcare professional must assist in dosage programming of the device prior to use, based on various patient- specific criteria and targets.

For additional product and safety information, please consult the Instructions for Use and bit. The system is intended to complement, not replace, information obtained from standard blood glucose monitoring devices, and is not recommended for people who are unwilling or unable to perform a minimum of two meter blood glucose tests per day, or for people who are unable or unwilling to maintain contact with their healthcare professional.

The system requires a functioning mobile electronic device with correct settings. If the mobile device is not set up or used correctly, you may not receive sensor glucose information or alerts.

The device may remain in place for up to 72 hours to accommodate multiple injections without the discomfort of additional needle sticks. Prescription required. Create an account on UpScript website and complete an online medical questionnaire. Speak one on one with a licensed healthcare professional.

If prescribed, InPen will be an additional cost. Yes, talk to a healthcare provider. No, back to Medtronic to learn more about InPen. You authorize Medtronic MiniMed, Inc. This authorization will expire three 3 years from the later of the date you submit this authorization online; or ii the last date products or services were received from Medtronic, but may expire sooner if you revoke it by following the instructions below.

You have the right to revoke this authorization at any time by i e-mailing takecontrol medtronic. com; or ii signing into your myHome profile and updating my communication preferences at www.

A revocation will not affect actions Medtronic Diabetes has already taken based on this authorization. Information disclosed pursuant to this authorization may be re-disclosed by the recipient of the information and may no longer be protected by the federal privacy standards.

You have the right to refuse to sign this authorization. Refusal to sign will not affect your treatment or health insurance eligibility or benefits. Contact our Customer Service Center at , or by email at takecontrol medtronic. Medtronic makes no guarantees that using the third-party website will result in your desired outcome.

It is wholly and solely your responsibility to assess the qualifications of a potential physician. Medtronic recommends that you meet and discuss the benefits and risks of all potential treatments with the potential physician. En Español. The pen Cap.

The app Current glucose. Ready to try it? Complete our form and a therapy specialist will reach out to discuss your options. I'd also like more information about:.

Continuous glucose monitoring CGM. How do you manage your diabetes? Insulin shots. How many shots per day? Our smart pens are approved for the continuous delivery of insulin, so this device may not be a good fit for you at this time.

Which insulin pump do you use? Medtronic Insulin Pump. How long have you owned your Medtronic pump? Less than 4 years. Please specify which pump? What type of diabetes do you or your loved one have?

Type 1 diabetes. Humalog ®. At this time, your insulin is not compatible with the InPen. InPen works with the following short-acting insulins only: Novolog, Humalog, and Fiasp. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe.

Primary insurance type? Commercial Insurance. Insurance Provider Name. Member ID. Group Number. Date of Birth. Is the policy holder the person living with diabetes?

I have read and acknowledge the notice of privacy practices and privacy policy. I hereby give my informed consent and permission to Medtronic MiniMed, Inc. and its affiliates, to perform an insurance verification of benefits for the MiniMed insulin pump system and to request a copy of my prescription for the MiniMed insulin pump system from my healthcare provider.

Subscribe to our newsletter, News to Infuse. Dosing calculator. Dose reminders Avoid missed insulin doses The InPen app can help you avoid missed insulin doses. Carb counting support Estimate carbs or choose a fixed dose The InPen app can help you estimate carbs based on your meal size.

Digital logbook Track dosing data on your phone The InPen app works like a digital logbook, tracking your dosing data on your phone. Diabetes technology could be doing a lot more for you.

Products sold separately. Lighten your diabetes management load The InPen gives me so much freedom.

The three hallmarks of a data-driven practice model for intensive insulin therapy include 5 :. ADA Recommendations Regarding Insulin Delivery 7 7. Inputting the correct, individualized settings in the smart insulin pen is critical for precise insulin management.

It is also important to assess and optimize basal insulin prior to fine-tuning the insulin therapy settings. It will be necessary to refine these insulin therapy settings over time as life and diabetes evolve; pediatric patients grow, activity, schedules, and living situations change and weight is gained or lost.

Integrated data reports from smart insulin pens enable the use of data to optimize the insulin regimen and fine-tune therapy settings. These data reports are available remotely enabling remote patient monitoring and virtual care facilitating more timely therapy adjustments.

Insulin pens have consistently outperformed syringes as delivery devices due to their greater accuracy and precision of dosing, ease-of-use, and patient preference. These advantages make them better suited to administer insulin in hypoglycemia-prone insulin-sensitive people with T1D, particularly younger children 1.

Aanstoot et al, emphasize the importance of 0. With standard insulin pens, individuals must round their dose to the nearest whole unit, thereby administering more or less insulin than required.

Half-unit insulin pens offer finer insulin dosing which may help improve overall glycemia and potentially prevent hypoglycemia. Patients using insulin-to-carbohydrate ratios to determine insulin dosing may especially benefit from half-unit insulin delivery.

Currently, five half-unit insulin pens are commercially available in the United States: HumaPen Luxura® HD, NovoPen Echo®, JuniorSTAR®, Humalog® Junior Kwikpen, and InPen TM smart insulin pen.

All pens except the JuniorSTAR® have demonstrated accuracy at 0. Priming before each insulin dose is an important part of precision dosing. Priming removes air from the needle and cartridge that may collect during normal use ensuring the full dose is delivered.

It is important that pen users prime before every injection. A stage 4 smart insulin pen must be able to differentiate prime from therapy doses 6. This is necessary in order to accurately track active insulin or insulin on board.

In order to safely correct between mealtime doses, it is essential that active insulin be accurately tracked. InPen TM smart insulin pen, the first FDA-cleared, Stage 4 Smart Insulin Pen, is able to do this based on a proprietary algorithm.

Additionally, users are able to indicate if a dose labeled prime is actually a therapeutic dose or vice versa. It is important to not assume an individual who has had diabetes for years knows how to inject correctly. Ask individuals to periodically demonstrate how they inject so that problems with the injection technique may be uncovered and corrected.

Even in a virtual visit, the camera can be used to demonstrate the correct insulin injection technique. Also important is proper site rotation. Clinicians should also be sure to discuss how individuals are storing their extra insulin cartridges, pens, and basal insulin and ensure individuals or keeping track of insulin expiration dates.

It will also alert if the pen and cartridge have been exposed to unsafe temperatures. To be successful in their glucose regulation, many people on intensive insulin therapy use carbohydrate counting to measure the carbohydrate content of the meal and calculate the exact insulin dose needed to maintain optimal postprandial glycemia.

These ratios may vary throughout the day, depending on meal timing and other factors, and is frequently more variable in pediatric populations due to their erratic eating habits, physical activity, and changing metabolism throughout development.

Matching carbohydrate intake and the insulin requirement requires both accurate and precise delivery of insulin to address metabolic needs, minimize glycemic variability, and optimize glycemia.

Smart Insulin Pens facilitate calculation and delivery of more exact bolus doses for meals and corrections. In addition to dosing accurately, bolus insulin injection must be timed appropriately before the meal to avoid post meal glucose spikes 9.

Insulin pens have shown a positive impact on the health-related quality of life with less frequent and less severe episodes of hypoglycemia 1. Outcomes such as treatment satisfaction, ease-of-use, discreetness, convenience and flexibility, injection pain, and patient preference all favor the use of insulin pens1.

Insulin pens with 0. I'd also like more information about:. Continuous glucose monitoring CGM. How do you manage your diabetes? Insulin shots. How many shots per day? Our smart pens are approved for the continuous delivery of insulin, so this device may not be a good fit for you at this time.

Which insulin pump do you use? Medtronic Insulin Pump. How long have you owned your Medtronic pump? Less than 4 years. Please specify which pump? What type of diabetes do you or your loved one have? Type 1 diabetes. Humalog ®. At this time, your insulin is not compatible with the InPen. InPen works with the following short-acting insulins only: Novolog, Humalog, and Fiasp.

Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe. Primary insurance type? Commercial Insurance. Insurance Provider Name. Member ID. Group Number.

Date of Birth. Is the policy holder the person living with diabetes? I have read and acknowledge the notice of privacy practices and privacy policy. I hereby give my informed consent and permission to Medtronic MiniMed, Inc.

and its affiliates, to perform an insurance verification of benefits for the MiniMed insulin pump system and to request a copy of my prescription for the MiniMed insulin pump system from my healthcare provider. Subscribe to our newsletter, News to Infuse.

Dosing calculator. Dose reminders Avoid missed insulin doses The InPen app can help you avoid missed insulin doses. Carb counting support Estimate carbs or choose a fixed dose The InPen app can help you estimate carbs based on your meal size.

Digital logbook Track dosing data on your phone The InPen app works like a digital logbook, tracking your dosing data on your phone. Diabetes technology could be doing a lot more for you. Products sold separately. Lighten your diabetes management load The InPen gives me so much freedom.

Mattie , mom of two, living with type 1 diabetes Compensated for their time. Thoughts and opinions are their own. Individual results may vary. Lighten your diabetes management load I love the dosing recommendations. It allows me to keep on track so I'm not taking too much insulin and then having to deal with lows.

Iaishia , living with type 1 diabetes Compensated for their time. Real customers. Real insights. A therapy helping people living with diabetes manage their insulin dosing more easily.

BEN "I absolutely LOVE my InPen! The support you need, when you need it Whether you're new to injection therapy or an experienced user — our support is tailored to you.

Hands-on product training In-person or online trainings help you get started on the right foot and make sure you have everything you need to be successful on your new therapy. Online educational resources Interested in learning more about your diabetes device on your own?

Talking to your healthcare provider soon? Download the guide. Looking for more? Join the list. Are you over age 13? Yes No. Please ask a parent or guardian to complete this form. Frequently asked questions What is the InPen?

How much does InPen cost? Are insulin cartridges included? Cartridges are not included with InPen. Cartridges can be ordered from the same pharmacy where you get your other diabetes supplies. InPen is compatible with Humalog, Novolog and Fiasp U 3.

Does InPen work with long-acting insulin? The InPen app allows you to manually log your long-acting insulin doses and set up dose reminders to take your long-acting insulin. InPen works with the following short-acting insulins: Novolog, Humalog, and Fiasp.

Can I pair more than one InPen to the app? What is active insulin and how is it shown in the app? Active Insulin, also known as insulin-on-board IOB , is an estimate of how much insulin from recent doses is still active in your body.

For example, if you take a 5 unit dose, there will initially be a full 5. Over several hours this will decrease as your body uses the insulin. The InPen app shows active insulin from rapid-acting and mealtime insulin only, not long-acting or basal insulin.

How is active insulin shown in the app? Active insulin is shown on the homescreen below the calculate dose button. This number shows your total active insulin based on all rapid-acting and mealtime doses from the past eight hours. Support User Guides Training Download Brochure Clinicians. Medtronic has partnered with UpScript Health, a telehealth provider.

UpScript will connect you with an independent, licensed healthcare provider to help you get InPen if right for you. If InPen is prescribed, pick it up from your local pharmacy.

Yes, talk to a healthcare provider No, back to Medtronic to learn more about InPen. First name.

It will also alert if the pen and cartridge have been exposed to unsafe temperatures. To be successful in their glucose regulation, many people on intensive insulin therapy use carbohydrate counting to measure the carbohydrate content of the meal and calculate the exact insulin dose needed to maintain optimal postprandial glycemia.

These ratios may vary throughout the day, depending on meal timing and other factors, and is frequently more variable in pediatric populations due to their erratic eating habits, physical activity, and changing metabolism throughout development.

Matching carbohydrate intake and the insulin requirement requires both accurate and precise delivery of insulin to address metabolic needs, minimize glycemic variability, and optimize glycemia. Smart Insulin Pens facilitate calculation and delivery of more exact bolus doses for meals and corrections.

In addition to dosing accurately, bolus insulin injection must be timed appropriately before the meal to avoid post meal glucose spikes 9.

Insulin pens have shown a positive impact on the health-related quality of life with less frequent and less severe episodes of hypoglycemia 1. Outcomes such as treatment satisfaction, ease-of-use, discreetness, convenience and flexibility, injection pain, and patient preference all favor the use of insulin pens1.

Insulin pens with 0. Half-unit insulin pens are also evolving with technological advances such as the stage 4 smart insulin pen, InPen TM smart insulin pen linked by Bluetooth® to a smart phone application that automatically records doses and incorporates a dose calculator and optional dose reminders to support precise insulin management.

Smart insulin pens connect to a mobile app to provide dosing calculations, reminders and CGM system integration. Aanstoot HJ, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision Dosing of Rapid-Acting Insulin Matters. Diab Technol Ther. McKnight JA, Wild SH, Lamb MJ, et al. Diabet Med.

Miller KM, Foster NC, Beck RW, et al. Diabetes Care. Beck RW, Miller KM, Foster NC: The T1D Exchange Clinic Network and Registry: 10 Years of Enlightenment On the State Of Type 1 Diabetes In the United States. Kerr D, Warshaw H, Choi NY.

Smart Insulin Pens Will Address Unmet Needs for People with Diabetes Using Insulin. Endocrine Today. American Diabetes Association Diabetes Technology: Standards of Medical Care in Diabetes — Frid AH, Kreugl G, Grassi G, Halmi S. Whether these can be sensitive enough to be modulated by changes within the physiological range remains to be determined, but if so, this would be an important new tool in the management of diabetes.

Other types of glucose-responsive insulins are being developed elsewhere. The synthetic hinge exploits naturally occurring processes and introduces fewer external or artificial elements compared to other approaches.

His team is already working on glucose-responsive insulin candidates that open and close at the desired high and low glucose thresholds, which are respectively 70 to milligrams per deciliter.

By replacing the fructose sensor with glucose sensors, a revolutionary insulin therapy may be closer than we think. Jarosinski, PhD, and Deepak Chatterjee, PhD, from Indiana University; Nelson B. Phillips, PhD, from Case Western Reserve University; Jeremy Gleaton, PhD, Yule Liu, PhD, Laurie Broadwater, PhD, Thomas Hattier, PhD, and M.

Dodson Michael, PhD, from Thermalin, Inc; and Michael C. Lawrence from the University of Melbourne. This work is supported in part by grants from the JDRF, the Leona M. and Harry B. Helmsley Charitable Trust, and the National Institutes of Health R01 DK and R01 DK Disotuar MM, Chen D, Lin N-P, Chou DH-C Glucose-responsive insulin through bioconjugation approaches.

J Diabetes Sci Technol 14 2 — NIDDK Advances and emerging opportunities in diabetes research: a Strategic Planning report of the Diabetes Mellitus Interagency Coordinating Committee.

Available from: www. Accessed 31 Jan Insel RA, Deecher DC, Brewer J Juvenile Diabetes Research Foundation: mission, strategy, and priorities. Diabetes 61 1 — Halvorson M, Carpenter S, Kaiserman K, Kaufman FR A pilot trial in pediatrics with the sensor-augmented pump: combining real-time continuous glucose monitoring with the insulin pump.

J Ped 1 — Ravaine V, Ancla C, Catargi B Chemically controlled closed-loop insulin delivery. J Control Release 1 :2— Hoeg-Jensen T, Ridderberg S, Havelund S et al Insulins with built-in glucose sensors for glucose responsive insulin release.

J Pept Sci 11 6 — Boughton CK, Hovorka R New closed-loop insulin systems. Vegas AJ, Veiseh O, Gürtler M et al Long-term glycemic control using polymer-encapsulated human stem cell—derived beta cells in immune-competent mice. Nat Med 22 3 Chen Z, Hu Q, Gu Z Leveraging engineering of cells for drug delivery.

Acc Chem Res 51 3 — Thabit H, Hovorka R Coming of age: the artificial pancreas for type 1 diabetes. Diabetologia 59 9 — Garg SK, Weinzimer SA, Tamborlane WV et al Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes.

Diabetes Techn Therap 19 3 — Hanaire H, Franc S, Borot S et al Efficacy of the Diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. Diabetes Obes Metab 22 3 — Genuth SM Metabolic clearance of insulin in man.

Diabetes 21 10 — Breton M, Farret A, Bruttomesso D et al Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 61 9 — Cypryk K, Wyrębska-Niewęgłowska A New faster-acting insulin Fiasp®—do we need a new meal-time insulin?

Clin Diabetol 7 6 — Majdpour D, Yale J-F, Legault L et al novel fully automated Fiasp-plus-pramlintide artificial pancreas for type 1 diabetes: randomized controlled trial. Can J Diabetes 44 7 :S4—S5. Linnebjerg H, Zhang Q, LaBell E et al Pharmacokinetics and glucodynamics of ultra rapid Lispro URLi versus Humalog ® Lispro in younger adults and elderly patients with type 1 diabetes mellitus: a randomised controlled trial.

Clin Pharm 59 12 — Blevins T, Zhang Q, Frias JP, Jinnouchi H, Chang AM Randomized double-blind clinical trial comparing ultra rapid lispro with Lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D.

Diabetes Care 43 12 — Lougheed WD, Zinman B, Strack TR et al Stability of insulin lispro in insulin infusion systems. Diabetes Care — Mudaliar SR, Lindberg FA, Joyce M et al Insulin aspart B28 Asp-insulin : a fast-acting analog of human insulin. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.

Exp Clin Endocrinol Diabetes — Bakhtiani PA, Caputo N, Castle JR et al A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient.

J Diabetes Sci Technol 9 1 — Jacobs PG, El Youssef J, Reddy R et al Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.

Diabetes Obes Metab 18 11 — Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.

Lancet Diabetes Endo 3 1 — Haidar A, Legault L, Matteau-Pelletier L et al Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.

Lancet Diabetes Endo 3 8 — Haidar A Insulin-and-glucagon artificial pancreas versus insulin-alone artificial pancreas: a short review. Diabetes Spectrum 32 3 — Castle JR, El Youssef J, Wilson LM et al Randomized outpatient trial of single-and dual-hormone closed-loop systems that adapt to exercise using wearable sensors.

Diabetes Care 41 7 — Blauw H, Keith-Hynes P, Koops R, DeVries JH A review of safety and design requirements of the artificial pancreas. Ann Biomed Eng 44 11 — El-Khatib FH, Balliro C, Hillard MA et al Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.

Lancet — Jackson MA, Caputo N, Castle JR, David LL, Roberts CT, Ward WK Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas.

Curr Diabetes Rep 12 6 — Ribet F, Stemme G, Roxhed N Ultra-miniaturization of a planar amperometric sensor targeting continuous intradermal glucose monitoring. Biosensors Bioelectr — Graf A, McAuley SA, Sims C et al Moving toward a unified platform for insulin delivery and sensing of inputs relevant to an artificial pancreas.

J Diabetes Sci Tech Schade DS, Eaton RP, Friedman JE, Spencer WJ Normalization of plasma insulin profiles with intraperitoneal insulin in diabetic man.

Diabetologia — Schade DS, Eaton P The peritoneum—a potential insulin delivery route for a mechanical pancreas. Diabetes Care 3 2 — Irsigler K, Kritz H, Hagmüller G et al Long-term continuous intraperitoneal insulin infusion with an implanted remote-controlled insulin infusion device.

Diabetes 30 12 — Renard E, Boutleau S, Jacques-Apostol D et al Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility.

Saudek CD, Duckworth WC, Giobbie-Hurder A et al Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group.

JAMA — Bally L, Thabit H, Hovorka R Finding the right route for insulin delivery—an overview of implantable pump therapy. Expert Opin Drug Deliv 14 9 — Jeandidier N, Boivin S, Sapin R et al Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Hua QX, Nakagawa SH, Jia W et al Design of an active ultrastable single-chain insulin analog: synthesis, structure, and therapeutic implications.

J Biol Chem — Vinther TN, Norrman M, Ribel U et al Insulin analog with additional disulfide bond has increased stability and preserved activity. Protein Sci 22 3 — Wu F, Mayer JP, Gelfanov VM, Liu F, DiMarchi RD Synthesis of four-disulfide insulin analogs via sequential disulfide bond formation.

J Org Chem 82 7 — Xiong X, Blakely A, Karra P et al Novel four-disulfide insulin analog with high aggregation stability and potency. Chem Sci 11 1 — Tycko R Solid-state NMR studies of amyloid fibril structure. Annu Rev Phys Chem — Tycko R, Ishii Y Constraints on supramolecular structure in amyloid fibrils from two-dimensional solid-state NMR spectroscopy with uniform isotopic labeling.

J Am Chem Soc — Dobson CM Protein folding and misfolding. Nature — Wang J, Wang Z, Yu J, Kahkoska AR, Buse JB, Gu Z Glucose-responsive insulin and delivery systems: innovation and translation. Adv Mat 32 13 Shen D, Yu H, Wang L et al Recent progress in design and preparation of glucose-responsive insulin delivery systems.

J Control Release — Lorand JP, Edwards JO Polyol complexes and structure of the benzeneboronate ion. J Org Chem 24 6 — Norrild JC, Eggert H Evidence for mono-and bisdentate boronate complexes of glucose in the furanose form. Application of 1 JC-C coupling constants as a structural probe.

J Am Chem Soc 5 — Wang C, Ye Y, Sun W et al Red blood cells for glucose-responsive insulin delivery. Adv Mat 29 18 Yang J, Wang F, Lu Y et al Recent advance of erythrocyte-mimicking nanovehicles: from bench to bedside. Brownlee M, Cerami A Glycosylated insulin complexed to concanavalin A.

Biochemical basis for a closed-loop insulin delivery system. Diabetes 32 6 — Ballerstadt R, Evans C, McNichols R, Gowda A Concanavalin A for in vivo glucose sensing: a biotoxicity review. Biosens Bioelectron 22 2 — Coutinho A, Larsson EL, Grönvik KO, Andersson J Studies on T lymphocyte activation II.

The target cells for concanavalin A-induced growth factors. Eur J Immun 9 8 — Karnati VV, Gao X, Gao S et al A glucose-selective fluorescence sensor based on boronicacid-diol recognition. Bioorg Med Chem Lett 12 23 — Fang H, Kaur G, Wang B Progress in boronic acid-based fluorescent glucose sensors.

J Fluoresc 14 5 — Peters JA Interactions between boric acid derivatives and saccharides in aqueous media: structures and stabilities of resulting esters. Coord Chem Rev — Zhao R, Lu Z, Yang J, Zhang L, Li Y, Zhang X Drug delivery system in the treatment of diabetes mellitus.

Frontiers Bioengin Biotechn Jin X, Zhang X, Wu Z et al Amphiphilic random glycopolymer based on phenylboronic acid: synthesis, characterization, and potential as glucose-sensitive matrix.

Biomacromol 10 6 — Wang Y, Huang F, Sun Y, Gao M, Chai Z Development of shell cross-linked nanoparticles based on boronic acid-related reactions for self-regulated insulin delivery.

J Biomater Sci Polym Ed 28 1 — Wang H, Yi J, Yu Y, Zhou S NIR upconversion fluorescence glucose sensing and glucose-responsive insulin release of carbon dot-immobilized hybrid microgels at physiological pH. Nanoscale 9 2 — Dong Y, Wang W, Veiseh O et al Injectable and glucose-responsive hydrogels based on boronic acid—glucose complexation.

Langmuir 32 34 — Zion TC, Tsang HH, Ying JY Glucose-sensitive nanoparticles for controlled insulin delivery. Li X, Fu M, Wu J et al pH-sensitive peptide hydrogel for glucose-responsive insulin delivery.

Acta Biomater — Anirudhan T, Nair AS, Nair SS Enzyme coated beta-cyclodextrin for effective adsorption and glucose-responsive closed-loop insulin delivery.

Int J Biol Macromol — Shi D, Ran M, Zhang L et al Fabrication of biobased polyelectrolyte capsules and their application for glucose-triggered insulin delivery. ACS Appl Mater Interfaces 8 22 — Taylor MJ, Chauhan KP, Sahota TS Gels for constant and smart delivery of insulin.

Brit J Diabetes 20 1 — Gu Z, Dang TT, Ma M et al Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. ACS Nano 7 8 — Yesilyurt V, Webber MJ, Appel EA, Godwin C, Langer R, Anderson DG Injectable self-healing glucose-responsive hydrogels with pH-regulated mechanical properties.

Adv Mater 28 1 — Ito Y, Imanishi Y Protein device for glucose-sensitive release of insulin. Design and synthesis of a protein device that releases insulin in response to glucose concentration.

Bioconjug Chem 5 1 — Hilgenfeld R, Seipke G, Berchtold H, Owens DR The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 74 8 — Gillies PS, Figgitt DP, Lamb HM Insulin glargine.

Drugs 59 2 — Kashyap N, Steiner SS, Pohl R inventors; Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels. Kaarsholm NC, Lin S, Yan L et al Engineering glucose responsiveness into insulin.

Diabetes 67 2 — Yang R, Wu M, Lin S et al A glucose-responsive insulin therapy protects animals against hypoglycemia. JCI Insight 3 1 :e Yang JF, Gong X, Bakh NA et al Connecting rodent and human pharmacokinetic models for the design and translation of glucose-responsive insulin.

Diabetes 69 8 — Taylor SI, DiMarchi RD Smarter modeling to enable a smarter insulin. Visser SA, Kandala B, Fancourt C, Krug AW, Cho CR A model-informed drug discovery and development strategy for the novel glucose-responsive insulin MK enabled rapid decision making.

Clin Pharm Therap 6 — Friedman S, Pizer R Mechanism of the complexation of phenylboronic acid with oxalic acid. Reaction which requires ligand donor atom protonation.

J Am Chem Soc 97 21 — Springsteen G, Wang B A detailed examination of boronic acid—diol complexation. Tetrahedron 58 26 — Wu X, Li Z, Chen X-X, Fossey JS, James TD, Jiang Y-B Selective sensing of saccharides using simple boronic acids and their aggregates.

Chem Soc Rev 42 20 — Glucose-dependent insulins. US patent 7,, B2. Glucose dependent release of insulin from glucose sensing insulin derivatives. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

Pharm Res 29 8 — Chou DH-C, Webber MJ, Tang BC et al Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc Natl Acad Sci 8 — Wang J, Yu J, Zhang Y et al Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia.

Proc Natl Acad Sci 22 — Jensen KJ, Mannerstedt K, Mishra NK et al An aldehyde responsive, cleavable linker for glucose responsive Insulins. Menting JG, Whittaker J, Margetts MB et al How insulin engages its primary binding site on the insulin receptor. Menting JG, Yang Y, Chan SJ et al Protective hinge in insulin opens to enable its receptor engagement.

Proc Natl Acad Sci 33 :E—E Scapin G, Dandey VP, Zhang Z et al Structure of the insulin receptor-insulin complex by single-particle cryo-EM analysis.

Weis F, Menting JG, Margetts MB et al The signalling conformation of the insulin receptor ectodomain. Nat Commun 9 1 Weiss M inventor; Case Western Reserve University, assignee. Insulin analogues with a glucose-regulated conformational switch. US patent 10,, B2.

Angyal SJ The composition of reducing sugars in solution. In: Tipson RS, Horton D eds Advances in carbohydrate chemistry and biochemistry, vol Elsevier, Amsterdam, pp 15— Google Scholar. Bérubé M, Dowlut M, Hall DG Benzoboroxoles as efficient glycopyranoside-binding agents in physiological conditions: structure and selectivity of complex formation.

J Org Chem 73 17 —